Lupin: Bernstein on Lupin Maintains Outperform with Target Price of ₹2,707 as its favorable Kalydeco patent judgment removes the key barrier to launching ivacaftor with 180-day exclusivity, potentially adding US$20–30mn annual US sales and strengthening its US respiratory franchise.

 27 Aug 2026 08:55 AM

Lupin: Bernstein on Lupin Maintains Outperform with Target Price of ₹2,707 as its favorable Kalydeco patent judgment removes the key barrier to launching ivacaftor with 180-day exclusivity, potentially adding US$20–30mn annual US sales and strengthening its US respiratory franchise.

Lupin: Citi on Lupin Downgrades to Sell with Target Price of ₹2,050 (cut from ₹2,540) as the US base business loses momentum, US sales are expected to decline to US$975mn by FY29E with margins falling to ~20%, while Apixaban offers only short-lived FY28E support and other biosimilar/inhaler opportunities remain unfiled.

 27 Aug 2026 08:55 AM

Lupin: Citi on Lupin Downgrades to Sell with Target Price of ₹2,050 (cut from ₹2,540) as the US base business loses momentum, US sales are expected to decline to US$975mn by FY29E with margins falling to ~20%, while Apixaban offers only short-lived FY28E support and other biosimilar/inhaler opportunities remain unfiled.

Lupin Limited: Signs Exclusive Deal With Visus Therapeutics For YuveziTM In Europe, With Total Possible Payment Up To €75 Million Including Strategic Funds And Milestone Payouts.

 20 Aug 2026 10:47 AM

Lupin Limited: Signs Exclusive Deal With Visus Therapeutics For YuveziTM In Europe, With Total Possible Payment Up To €75 Million Including Strategic Funds And Milestone Payouts.

Lupin: Company Gets U.S. FDA Approval For Pitolisant Tablets

 17 Aug 2026 12:20 PM

Lupin: Company Gets U.S. FDA Approval For Pitolisant Tablets

Lupin: Company Gets Approval For Oral Suspension Of Sodium Zirconium Cyclosilicate In The U.S.

 10 Aug 2026 09:35 PM

Lupin: Company Gets Approval For Oral Suspension Of Sodium Zirconium Cyclosilicate In The U.S.

Lupin: Company Gets US FDA Approval For Sodium Zirconium Cyclosilicate Oral Suspension

 10 Aug 2026 06:02 PM

Lupin: Company Gets US FDA Approval For Sodium Zirconium Cyclosilicate Oral Suspension

Lupin: Company Confirms Expectations For High Single-Digit Revenue Growth And About 25% EBITDA Margins This Year. U.S. Business Forecasted To Be Between $1.1 Billion And $1.2 Billion, With Base Business Growth, Injectable Launches, And Pegfilgrastim Balancing Increased Competition From Products Like Mirabegron And Tolvaptan.

 10 Aug 2026 08:57 AM

Lupin: Company Confirms Expectations For High Single-Digit Revenue Growth And About 25% EBITDA Margins This Year. U.S. Business Forecasted To Be Between $1.1 Billion And $1.2 Billion, With Base Business Growth, Injectable Launches, And Pegfilgrastim Balancing Increased Competition From Products Like Mirabegron And Tolvaptan.

Lupin: U.S. Business Anticipated To Return To Growth Starting Fiscal Year '28, Supported By Strong Pipeline Of Exclusive First-To-Files, Biosimilars, And 505(B)(2) Products.

 10 Aug 2026 08:58 AM

Lupin: U.S. Business Anticipated To Return To Growth Starting Fiscal Year '28, Supported By Strong Pipeline Of Exclusive First-To-Files, Biosimilars, And 505(B)(2) Products.

LUPIN: Q1 CONS NET PROFIT 14.15B RUPEES VS 12.2B (YOY); EST 13.77B

 06 Aug 2026 09:59 PM

LUPIN: Q1 CONS NET PROFIT 14.15B RUPEES VS 12.2B (YOY); EST 13.77B

LUPIN: Q1 REVENUE 82.77B RUPEES VS 61.6B (YOY); EST 79B

 06 Aug 2026 09:59 PM

LUPIN: Q1 REVENUE 82.77B RUPEES VS 61.6B (YOY); EST 79B

LUPIN: Q1 EBITDA 24.5B RUPEES VS 17.3B (YOY); EST 22.23B || Q1 EBITDA MARGIN 29.59% VS 27.56% (YOY); EST 28.1%

 06 Aug 2026 09:59 PM

LUPIN: Q1 EBITDA 24.5B RUPEES VS 17.3B (YOY); EST 22.23B || Q1 EBITDA MARGIN 29.59% VS 27.56% (YOY); EST 28.1%

Lupin: Receives U.s. FDA Approval For Diazepam Injection Usp

 31 Jul 2026 05:24 PM

Lupin: Receives U.s. FDA Approval For Diazepam Injection Usp

Lupin: Co. Gets U.S. FDA Approval For Sugammadex Injection, Similar To Merck's Bridion Injection, For Reversing Neuromuscular Blockade During Surgery.

 31 Jul 2026 11:15 AM

Lupin: Co. Gets U.S. FDA Approval For Sugammadex Injection, Similar To Merck's Bridion Injection, For Reversing Neuromuscular Blockade During Surgery.

Lupin: Company Receives U.S. FDA Approval And Launches Sugammadex Injection

 30 Jul 2026 10:13 PM

Lupin: Company Receives U.S. FDA Approval And Launches Sugammadex Injection

Lupin: Company Gets Approval For Diazepam Injection In The U.S.

 28 Jul 2026 09:02 PM

Lupin: Company Gets Approval For Diazepam Injection In The U.S.

Lupin: Company To Hold Q1 Earnings Call On August 7 At 4:30 PM

 22 Jul 2026 10:17 PM

Lupin: Company To Hold Q1 Earnings Call On August 7 At 4:30 PM

Lupin: Company To Review Q1 Results On August 6

 22 Jul 2026 04:38 PM

Lupin: Company To Review Q1 Results On August 6

Lupin: Company Grants Kaveri Therapeutics Exclusive License For Oncology Program And Acquires 82.2% Equity Stake For $1.6 Million.

 21 Jul 2026 08:36 AM

Lupin: Company Grants Kaveri Therapeutics Exclusive License For Oncology Program And Acquires 82.2% Equity Stake For $1.6 Million.

Lupin: Company Gets EIR From U.S. FDA For Somerset Facility With VAI Status

 02 Jul 2026 07:51 AM

Lupin: Company Gets EIR From U.S. FDA For Somerset Facility With VAI Status

Lupin: Netherlands Unit Nanomi Increases Share In Multicare Philippines To 99.89%

 01 Jul 2026 06:25 PM

Lupin: Netherlands Unit Nanomi Increases Share In Multicare Philippines To 99.89%